Vatole Pty Ltd v Boehringer Ingelheim KG

Vatole Pty Ltd (the applicant) sought to restrain Boehringer Ingelheim KG (the respondent) from infringing its registered trade mark 'Vatole' used in relation to pharmaceutical preparations for the treatment of cardiovascular disease. The applicant alleged that the respondent's proposed use of the trade mark 'Vatolex' for a similar pharmaceutical product would cause confusion and deception among consumers, thereby infringing its registered mark. The matter came before Justice Sullivan in the Federal Court of Australia.

The central legal issue before the Court was whether the respondent's proposed use of the trade mark 'Vatolex' constituted an infringement of the applicant's registered trade mark 'Vatole' under the *Trade Marks Act 1995* (Cth). This required the Court to assess the likelihood of deception or confusion among the relevant class of consumers, considering the similarity of the marks, the similarity of the goods, and the circumstances of their use.

Justice Sullivan applied the established principles for assessing trade mark infringement, focusing on the "imperfect recollection" of the average consumer. Her Honour found that while the marks shared some phonetic similarities, the presence of the additional syllable 'ex' in 'Vatolex' created a sufficient distinction. Furthermore, considering the nature of the goods (pharmaceuticals) and the likely carefulness of consumers when purchasing such products, the Court determined that there was no real likelihood of deception or confusion. The Court concluded that the respondent's proposed use of 'Vatolex' would not infringe the applicant's registered trade mark 'Vatole'.

The application for an interlocutory injunction was dismissed.